van Leeuwen Redmer, Eijkemans Marinus J C, Vingerling Johannes R, Hofman Albert, de Jong Paulus T V M, Simonsz Huib J
Department of Epidemiology and Biostatistics, Erasmus Medical Center, Rotterdam, the Netherlands.
Br J Ophthalmol. 2007 Nov;91(11):1450-1. doi: 10.1136/bjo.2006.113670. Epub 2007 May 23.
The excess risk of bilateral visual impairment (BVI; bilateral visual acuity <0.5) among individuals with amblyopia is an argument for screening for amblyopia, but data are scarce.
The risk was estimated by determining the incidence of BVI in the Rotterdam Study, a population-based cohort of subjects aged 55 years or over (n = 5220), including 192 individuals with amblyopia (3.7%). Using a multistate lifetable, the lifetime risk and excess period spent with BVI were determined.
The relative risk of BVI for amblyopes was 2.6 (95% confidence interval 1.4-4.5). For individuals with amblyopia, the lifetime risk of BVI was 18%, whereas they lived on average 7.2 years with BVI. For non-amblyopic individuals, these figures were 10% and 6.7 years, respectively.
Amblyopia nearly doubles the lifetime risk of BVI and affected individuals spent an extra six months with BVI. This study provides data for future cost-effectiveness analyses.
弱视患者发生双眼视力损害（BVI；双眼视力<0.5）的额外风险是进行弱视筛查的一个依据，但相关数据较少。
通过确定鹿特丹研究中BVI的发病率来估计风险，该研究是一项基于人群的队列研究，研究对象为55岁及以上的人群（n = 5220），其中包括192例弱视患者（3.7%）。使用多状态生命表确定了BVI的终生风险和与BVI相关的额外时间。
弱视患者发生BVI的相对风险为2.6（95%置信区间1.4 - 4.5）。对于弱视患者，BVI的终生风险为18%，而他们平均有7.2年处于BVI状态。对于非弱视个体，这些数字分别为10%和6.7年。
弱视使BVI的终生风险几乎增加一倍，且受影响个体处于BVI状态的时间额外增加了6个月。本研究为未来的成本效益分析提供了数据。
